Physician profile

Anthony Diaz

Farmington, CT

NPI 1922685015

$505.29

in general payments reported to CMS, 2019-2025

4 companies · $182 in 2025

The $182 reported for 2025 was more than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$277.16
Education$160.79

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Stryker Corporation $160.79 2024
Medtronic, INC. $130.67 2022-2025 Fusion, Aquamantys(Tm)
Microvention, INC. $118.83 2025 Sofia 6f-131cm Str
Astrazeneca Pharmaceuticals LP $95.00 2024 Andexxa

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anthony Diaz

$505.29

in general payments reported 2019-2025

Years
2022-2025
Top company
Stryker Corporation
Context
The $182 reported for 2025 was more than what a typical provider received nationally.

https://glasscript.com/doctor/11421733/anthony-diaz

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.